Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for CKD-Associated Calciphylaxis
NCT07708038Phase 1Not yet recruiting
- Sponsor
- Boston Medical Center
- Start
- Sep 2027
- Primary completion
- Mar 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tocilizumab in calciphylaxis (CUA), sponsored by Boston Medical Center. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 18 weeks and Feasibility of treatment at 18 weeks. Planned start Sep 2027; status: not yet recruiting.
02
Drugs
tocilizumab
03
Conditions
calciphylaxis (CUA)
Beyond the preview
Go deeper on NCT07708038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07708038.